Athersys to Present at BIO CEO Investor C
Post# of 1906
Athersys to Present at BIO CEO & Investor Conference | ||||||||||||
| ||||||||||||
Athersys, Inc. (Nasdaq:ATHX) announced today that Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer, will present at the 15 th Annual BIO CEO & Investor Conference to be held Monday, February 11, 2013, through Tuesday, February 12, 2013, at The Waldorf Astoria New York in New York City. Details of Athersys' participation are as follows:
About Athersys Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem ® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft-versus-host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com . The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548 CONTACT: William (B.J.) Lehmann, J.D. |